HHV8 ORF50 Antikörper (AA 2-100) (Cy3)
Kurzübersicht für HHV8 ORF50 Antikörper (AA 2-100) (Cy3) (ABIN672684)
Target
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 2-100
-
Kreuzreaktivität
- Virus
-
Kreuzreaktivität (Details)
- Human herpesvirus 8, Kaposi's sarcoma-associated herpesvirus
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from N-terminus of HHV8 ORF50 strain GK18
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- HHV8 ORF50 (Herpes Virus Type 8 ORF50 (HHV8 ORF50))
-
Andere Bezeichnung
- HHV8 ORF50
-
Substanzklasse
- Viral Protein
-
Hintergrund
-
Synonyms: HHV 8, Human Herpes Virus 8, Human herpesvirus 8, HHV8 ORF50, Kaposi's sarcoma associated herpes virus, Kaposi's sarcoma associated herpesvirus, KSHV, replication and transcription activator, RTA
Background: HHV8 has been found to be associated with three different diseases observed in AIDS patients, kaposi's sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease. To date there is much evidence to support a direct role for HHV8 in kaposi's sarcoma.
-
Gen-ID
- 4961526
-
UniProt
- F5HCV3
Target
-